Roche touts full da­ta for drug in first-line PIK3CA-mu­tat­ed breast can­cer

Roche’s breast can­cer com­bi­na­tion of in­avolis­ib plus pal­bo­ci­clib and ful­ves­trant showed off new da­ta Fri­day, with the com­pa­ny tout­ing a 57% re­duc­tion in the risk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER